U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019779) titled 'Study of CM518D1 in Patients With Advanced Solid Tumors' on May 26.
Brief Summary: This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.
Study Start Date: June 09
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
BIOLOGICAL: CM518D1
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
BIOLOGICAL: CM518D1
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
BIOLOGICAL: CM51...